IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
Authors
Keywords
-
Journal
Kidney International Reports
Volume 8, Issue 5, Pages 1043-1056
Publisher
Elsevier BV
Online
2023-03-04
DOI
10.1016/j.ekir.2023.02.1086
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy
- (2022) Jicheng Lv et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
- (2022) et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
- (2022) Jonathan Barratt et al. KIDNEY INTERNATIONAL
- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
- (2021) David C. Wheeler et al. KIDNEY INTERNATIONAL
- KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
- (2021) Brad H. Rovin et al. KIDNEY INTERNATIONAL
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study
- (2019) Simon Jarrick et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
- (2019) Hiddo J L Heerspink et al. LANCET
- Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
- (2019) Hiddo J L Heerspink et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Epidemiology of IgA Nephropathy: A Global Perspective
- (2018) Francesco Paolo Schena et al. SEMINARS IN NEPHROLOGY
- DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS
- (2018) Howard Trachtman et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease
- (2016) Radko Komers et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- IgA nephropathy
- (2016) Kar Neng Lai et al. Nature Reviews Disease Primers
- Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study
- (2015) V. Tesar et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Intensive Supportive Care plus Immunosuppression in IgA Nephropathy
- (2015) Thomas Rauen et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy
- (2014) D. de Zeeuw et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Endothelin and endothelin antagonists in chronic kidney disease
- (2014) Donald E Kohan et al. KIDNEY INTERNATIONAL
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
- Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease
- (2013) Sean J. Barbour et al. KIDNEY INTERNATIONAL
- Selective Endothelin-A Receptor Antagonism Reduces Proteinuria, Blood Pressure, and Arterial Stiffness in Chronic Proteinuric Kidney Disease
- (2011) Neeraj Dhaun et al. HYPERTENSION
- Predicting the Risk for Dialysis or Death in IgA Nephropathy
- (2011) F. Berthoux et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The incidence of primary glomerulonephritis worldwide: a systematic review of the literature
- (2010) A. McGrogan et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now